AdaptHealth Corp. Partners With Humana On Value-Based Care

AdaptHealth Corp. (NASDAQ:AHCO) a national leader in providing patient‐centered, healthcare‐at‐home solutions including home medical equipment, medical supplies, and related services, has entered into an agreement

AdaptHealth Corp. (NASDAQ:AHCO) a national leader in providing patientâ€centered, healthcareâ€atâ€home solutions including home medical equipment, medical supplies, and related services, has entered into an agreement to become the capitated provider of durable home medical equipment and supplies to Humana Medicare Advantage HMO members in 33 states, plus the District of Columbia. AdaptHealth’s agreement with Humana, which features a value-based pricing model replacing traditional fee-for-service, is expected to cover at least 1.0 million members.

“We are delighted that Humana has partnered with AdaptHealth to help its members achieve their best health at home,” said AdaptHealth CEO Steve Griggs. “Our unmatched nationwide network of more than 700 locations, a resilient supply chain, and a focus on technology and in-home service to improve patient care will deliver excellent value to Humana Medicare Advantage members.”

“The AdaptHealth-Humana partnership will also eliminate many of the burdens that patients face in ordering home medical equipment, and will reduce administrative costs for Humana, AdaptHealth, and our referring physicians” said Griggs.

The value-based agreement covers Humana’s Medicare Advantage HMO members in the states of: Alabama, Tennessee, Virginia, North Carolina, Georgia, South Carolina, Texas, Arkansas, Oklahoma, Illinois, Minnesota, North Dakota, South Dakota, Wisconsin, Nebraska, Iowa, Kansas, Missouri, District of Columbia, Delaware, Maryland, Pennsylvania, Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Vermont, California, Nevada, Colorado, and New Mexico.

Total
0
Shares
Related Posts
Read More

Ardelyx Earlier Provided Update On 2024 Strategic Priorities; Expects FY24 U.S. Net Product Sales Revenue For IBSRELA To Be Between $140M-$150M; As Of December 31, 2023, The Co Had Total Cash, Cash Equivalents And Short-Term Investments Of ~$184M

Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peakWebcast scheduled for 7:00 PM ET / 4:00 PM PT

ARDX